Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
  •  
  • Permission not
    granted for presentation
  •  
  •  
Optimization of glutaminase inhibitors for the treatment of cancer
Rene M. Lemieux
Agios Pharmaceuticals, Cambridge, MA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
  •  
  • Permission not
    granted for presentation
  •  
  •  
Discovery of in vivo inhibitors of Lactate Dehydrogenase A (LDHA)
Hans Purkey
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
Discovery of a Potent, Selective, NAMPT inhibitor from the Pyridyloxyacetyl-Dihydro-Isoquinoline-Sulfonamide series that demonstrated robust efficacy and improved tolerability with nicotinic acid co-administration
Timothy P. Burkholder
Eli Lilly and Company, Indianapolis, IN, United States
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Design of Small Molecules Targeting Tumor Metabolism
  •  
  • Permission not
    granted for presentation
  •  
  •  
MCT1: The journey from phenotypic screen hit to clinical candidate
Jon Winter
AstraZeneca R&D, Cheshire, United Kingdom
from AACR Annual Meeting 2015 on April 18, 2015 3:15 PM-5:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4